Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Today, Pfizer said that its phase 3 TALAPRO 2 trial of PARP drug Talzenna (talazoparib) in combination with its Astellas-partnered anti-androgen therapy Xtandi (enzalutamide) reduced radiographic ...

Pfizer has pledged a whopping $1 billion upfront ... with drugs like CDK4/6 inhibitor Ibrance (palbociclib), PARP inhibitor Talzenna (talazoparib), hormonal therapy Aromasin (exemestane) and ...

This time around, NICE assessed the med using a faster cost comparison process that compared Lynparza to Pfizer’s Talzenna in benefits and cost. Stallergenes Greer’s peanut allergy treatment ...

Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...

New Diagnostics, AI Breakthroughs, and Next-Gen Therapies Are Transforming the Oncology Market. The oncology sector is ...

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.